Categories Earnings, Retail

DSW Inc Q3 2018 results: Earnings jump on robust comp sales, but misses estimates

DSW Inc. (DSW) is posted upbeat third-quarter sales before the market opened on Tuesday, Dec. 11. Earnings grew ten-fold to $39.3 million or $0.48 per share but fell short of estimates, while revenue jumped 17.2% to $833 million. Comp-store sales grew 7.3%, excluding Canada retail segment.

The Street expected earnings of $0.53 per share on revenue of $785.6 million for the quarter.

DSW also raised its full-year outlook for adjusted EPS to $1.70-$1.85 per diluted share from the previous $1.60-$1.75 per share range. The footwear retailer also noted that the Camuto Group acquisition is expected to yield benefits starting in 2019.

DSW third quarter 2018 earnings infographic

Back in November, Foot Locker (FL) stock benefitted from upbeat third-quarter earnings and sales. The peer company reported earnings of $0.95 per share on revenue of $1.86 billion. Comp-store sales increased 2.9%, while gross margin expanded to 31.6%.

The run-up to the holiday season has been disappointing for the retail industry—with lackluster financial performance and weak guidance weighing down on the market value of several leading players. Concerns over the long-term headwinds to profitability looks to outweigh the positive factors like economic growth and low unemployment.

Foot Locker comp store sales trend vs DSW Inc

 

Except for Walmart (WMT), most retailers came out with unimpressive results for the most recent quarter. The underlining weakness in market sentiment is so strong that even Walmart’s shares remained in the red over the past week despite the company posting above-consensus third-quarter numbers.

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top